An open-label, dose-fixed, multi-group, single-center study Phase 1 Trial of Booster Vaccination Against COVID-19 with Whole-SARS-CoV-2-Virion Inactivated Vaccine KD-414 in Japan
Latest Information Update: 26 May 2025
At a glance
- Drugs KD 414 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 26 May 2025 New trial record